Tag

Fibrogen

All articles tagged with #fibrogen

business2 years ago•2 min saved

FGEN Stock Plummets on Second Lead Drug Failure.

Biotech company FibroGen's stock crashed to a record low after its lead asset, pamrevlumab, failed to meet the preset bar for treating idiopathic pulmonary fibrosis. This is the second failure for the drug, which also failed to make a difference in Duchenne muscular dystrophy earlier this month. FibroGen will scrap two final-phase studies of pamrevlumab in idiopathic pulmonary fibrosis and work to extend its cash runway in 2026 through a cost-cutting plan. The fall of FibroGen stock marked a record low in massive volume.

via Investor's Business Daily|

#business #drug-failure #fibrogen

healthcare2 years ago•0 min saved

FibroGen's Lead Drug Fails Again, Stock Crashes.

FibroGen's pamrevlumab failed in a Phase III study for idiopathic pulmonary fibrosis, marking the company's third late-stage miss in two months. The drug was not better than placebo at a lung function test and did not delay disease progression. However, it was generally safe and well-tolerated.

via Endpoints News|

#clinical-trials #fibrogen #healthcare

healthcare2 years ago•6 min saved

FibroGen's Pamrevlumab Faces Setbacks in Phase 3 Trials for Lung Fibrosis Treatment

FibroGen's Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of change from baseline in forced vital capacity (FVC) at week 48. The study compared treatment with pamrevlumab to placebo. Pamrevlumab was generally safe and well tolerated. FibroGen plans to implement a significant cost reduction effort in the U.S. with the intent to extend its cash runway into 2026.

via Yahoo Finance|

#clinical-trials #fibrogen #healthcare

healthcare2 years ago•0 min saved

FibroGen's Pamrevlumab Therapy Fails to Show Efficacy in Late-Stage Study.

FibroGen's lead candidate, pamrevlumab, has failed a Phase III study in Duchenne muscular dystrophy, causing shares to fall 9% in pre-market trading. The drug was being developed alongside anemia drug roxadustat, which has also faced multiple setbacks in clinical and regulatory trials.

via Endpoints News|

#clinical-trial #duchenne-muscular-dystrophy #fibrogen